Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Opsumit

Chemical Namemacitentan
Dosage FormTablet (oral; 10mg)
Drug ClassReceptor antagonists
SystemCardiovascular
CompanyActelion Pharmaceuticals
Approval Year2013

Indication

  • For the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization.
Last updated on 6/23/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Opsumit (macitentan) Prescribing Information.2021Actelion Pharmaceuticals US, Inc., South San Francisco, CA
Document TitleYearSource
Australian public assessment report for macitentan. 2014Australian Government: Department of Health
Assessment report: Opsumit. 2014EMA
Clinical review report: macitentan (Opsumit).2013CADTH
Pharmacoeconomic review report: macitentan (Opsumit).2013CADTH
Clinical review report: macitentan (Opsumit).2013CADTH
Document TitleYearSource
A Bayesian network meta-analysis of add-on drug therapies specific for pulmonary arterial hypertension.2020Annals of Pharmacotherapy
Efficacy and safety of the use of pulmonary arterial hypertension pharmacotherapy in patients with pulmonary hypertension secondary to left heart disease: a systematic review. 2019Pharmacotherapy
Document TitleYearSource
Canadian Cardiovascular Society/Canadian Thoracic Society position statement on pulmonary hypertension.2020Canadian Journal of Cardiology
Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report.2019Chest